Urology Doctors in Texarkana, TX Accepting Medicare

7 Urology doctors found. Showing 1 - 7

Joseph Sean Womack, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 5002 Cowhorn Creek Rd, Texarkana, TX 75503 Phone: 903-614-3000    Fax: 903-614-3525

Dr. Glen A Rountree, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 1902 Moores Ln, Texarkana, TX 75503 Phone: 903-792-7515    Fax: 903-791-8645

Patrick J Somerville, MD Urology Medicare: Not Enrolled in Medicare Practice Location: 1902 Moores Ln, Texarkana, TX 75503 Phone: 903-792-7515    Fax: 903-614-3525

Dr. Jason T Pickelman, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 1902 Moores Ln, Texarkana, TX 75503 Phone: 903-792-7515    Fax: 903-791-8645

Dr. Christopher Todd Payne, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 1902 Moores Ln, Texarkana, TX 75503 Phone: 903-792-7515    Fax: 903-791-8645

Dr. Cordell L Klein, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 1902 Moores Ln, Texarkana, TX 75503 Phone: 903-792-7515    Fax: 903-791-8645

Dr. George R Hunter, MD Urology Medicare: Not Enrolled in Medicare Practice Location: 1002 Texas Blvd, Ste 501, Texarkana, TX 75501 Phone: 903-792-7515

News Archive

Research identifies new gene fusions and mutations linked to GIST tumors

Researchers at UC San Diego Moores Cancer Center, with colleagues from Memorial Sloan Kettering Cancer Center and Fox Chase Cancer Center, have determined that a specific region of the small bowel, called the duodenal-jejunal flexure or DJF, shows a high frequency of gastrointestinal stromal tumors (GISTs) with mutations of the NF1 gene

Acceleron Pharma and Shire announce joint development of ACE-031 for DMD

Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, and Shire plc, the global specialty biopharmaceutical company, today announced a joint development and commercialization agreement for ACE-031 and other novel molecules targeting the activin receptor type IIB (ActRIIB) pathway. This pathway plays critical roles in regulating the growth of skeletal muscle.

Up to 80% of metastatic colorectal cancers spread to far areas before diagnoses

Up to 80% of metastatic colorectal cancers are likely to have spread to distant locations in the body before the original tumor has exceeded the size of a poppy seed, according to a study of nearly 3,000 patients by researchers at the Stanford University School of Medicine.

New screening method could catch organ rejection much earlier without a biopsy needle

Too often, it's only after a transplanted organ has sustained serious damage that a biopsy reveals the organ is in rejection. A new screening method using sensor particles and a urine test could catch rejection much earlier, more comprehensively, and without a biopsy needle.

Read more Medical News

› Verified 6 days ago